Interview With Rabbi Zac Kamenetz

Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

1. MindMed’s Mission
2. Their Talent acquisition
3. The Progress of their different clinical trials
4. The future

Timestamps:
0:00 – Intro
1:59 – MindMed’s Mission
4:36 – MMED’s talent acquisition
7:24 – MindMed’s clinical trial progress
10:48 – Psychiatry department : Project Lucy
14:17 – Addiction department : Project Layla (18MC)
18:33 – Pain department: Project Angie to treat pain card
22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
23:43 – MindMed (MMED / MNMD) and its future plans

Enjoy!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD

In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Mydecine (MYCO/MYCOF), Numinuss Wellness (NUMI), and Red Light Holland (TRIP).

We will cover the latest developments in the field writ large.
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

Time Stamps
0:00​ – Intro
0:35 – Imperial College Of London results of Study the effects of microdosing psychedelics and their impact on the psychedelic industry
5:45 – 15 Canadian healthcare professionals begin a historic psilocybin training program
6:55 – Chief of the Defense Force, Chris Barrie, is calling for psychedelic compounds like psilocybin and MDMA to be rescheduled
8:31 – A smartphone app called promises to induce a psychedelic like state (FUN)!
10:58 – MindMmed Stock News ( MMED/MMEDF/MMQ) and Company Updates
13:33 – Compass Pathways (CMPS) Stock News and Company Updates
15:22 – Atai Life Sciences Company News and IPO Speculation
16:42 – Numinus (NUMI) Stock News & 3 Company Updates
19:30 -Red Light Holland (TRIP) Stock News & Very Interesting Company Update
20:52 – Mydecine (MYCO/MYCOF) Stock News & Updates

So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor

Facebook: @thepsychedelicinvestor
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies.

Mind Medicine (MindMed), (NASDAQ: MNMD, NEO: MMED, DE: MMQ), announced that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany, conducted as part of MindMed’s ongoing collaboration with the UHB Liechti Lab.

STUDIES:
https://clinicaltrials.gov/ct2/show/NCT03912974?term=psilocybin+escitalopram&draw=2&rank=2

https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD+PSilocybin&draw=2&rank=1

https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/?fbclid=IwAR2_2fUvNf-VTF36Sv6Oz-XB8PTjscqjMWMFF5CKBvKQU2yLMOI_ZP4aq18
Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#mindmed #mmed #mnmdstock